CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 29, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22 nd Annual Global Healthcare Conference on September 6, 2024 at 12:20 p.m.
Following regulatory approval in the earlier line setting this quarter, Abecma generated $54 million U.S. commercial revenue and saw meaningful growth in demand Recent completion of Hemophilia A and gene editing technology sale to Novo Nordisk for up to $40 million reinforces exclusive focus on
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT) will announce its second quarter 2024 financial results on Wednesday, August 7, 2024 . A conference call and webcast will be held at 8:00 a.m. ET . Participants can access the conference call live via webcast
- Divestiture Supports Company Focus on Development and Commercialization of Abecma - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 26, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk .
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 23, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5 th Annual Oncology Innovation Summit: Insights for ASCO & EHA in a virtual fireside chat
U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial Launch Underway Completion of R&D Pipeline Divestiture to Regeneron Sets Company on Track to Focus Exclusively on Development and Commercialization of Abecma
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024 . A conference call and webcast will be held at 8:00 a.m. ET . Participants can access the conference call live via webcast which
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile Expanded approval brings this personalized CAR T cell therapy to more patients with relapsed or
- Company Now Exclusively Focused on Development and Commercialization of Abecma - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 1, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 20, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin , Chief Investment Officer, and Founder of Casdin Capital , and Charles Newton , Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the
